Indian Journal of Pharmacy and Pharmacology

Print ISSN: 2393-9079

Online ISSN: 2393-9087

CODEN : IJPPTK

Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award programs. With more...

Article type

Original Article


Article page

38-41


Authors Details

Vijay M. Motghare, Nikhil H. Dhargawe, Chaitali S. Bajait, Vijay Mahobia, AK Diwan


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 1521

PDF Downloaded: 557


Study of prescription patterns and adverse drug reaction monitoring in patients of oral cavity malignancies attending radiotherapy department in a tertiary care teaching institute


Original Article

Author Details : Vijay M. Motghare, Nikhil H. Dhargawe, Chaitali S. Bajait, Vijay Mahobia, AK Diwan

Volume : 4, Issue : 1, Year : 2017

Article Page : 38-41


Suggest article by email

Get Permission

Abstract

Objectives: To study prescriptions of patients having oral cavity malignancy on antineoplastic drugs and study adverse drug reaction occurred.
Methods: an observational study was carried out in radiotherapy out-patient department in tertiary care teaching institute, Nagpur after approval from Institutional Ethics Committee for 2 months period. In this prospective study, diagnosed cases of oral cavity malignancies were included. Epidemiological data and details of prescribed drugs were recorded. Collected data was analyzed for prescription pattern of antineoplastic drugs and reported adverse drug reactions.
Results: Out of 34 enrolled patients, majority were male (73.05%) with mean age 48 ± 13.29. Carcinoma of buccal mucosa (35.2%) was most common. Chemotherapy drugs commonly used were Cisplatin (79.4%), 5-fluorouracil (47%), Paclitaxel (41.1%), Carboplatin (20.5%), Docetaxel (20.5%). Monotherapy (Cisplatin) developed 4.6% ADRs, two drug therapy (Cisplatin+Paclitaxel, Cisplatin+5-fluorouracil, Carboplatin+Paclitaxel) developed 79% ADRs and three drug therapy (Cisplatin+Paclitaxel+5-fluorouracil, Cisplatin+Docetaxel+5-fluorouracil) developed 16.2% ADRs.
A total of 43 adverse reactions were reported during this study. Reactions observed were nausea (18.6%), vomiting (18.6%), anorexia (16.2%), alopecia (13.9%), diarrhea (2.3%), constipation (4.6%), weakness (18.6%), insomnia (2.3%), hemoptysis (2.3%) and black nails (2.3%). In Naranjo causality assessment, 62.7% of ADRs were probable and 37.2% were possible. In Hartwig and Siegel scale analysis, most reactions (76.7%) were of “mild” severity, 20.9% of reactions were of “moderate” severity, while 2.3% of reactions were of “severe” severity. Modified Schumock and Thornton criteria indicated that 44% of ADRs as “definitely preventable” and 55.8% of ADRs as “not preventable”.
Conclusion: Study concludes that antineoplastic drugs, Cisplatin, Carboplatin, Docetaxel, Paclitaxel and 5-fluorouracil were commonly prescribed. Higher incidence of ADRs was observed with two drug therapy as compared to single drug regimen.

Keywords: Oral malignancy, Antineoplastic drug, Adverse drug reaction (ADR)


How to cite : Motghare V M, Dhargawe N H, Bajait C S, Mahobia V, Diwan A, Study of prescription patterns and adverse drug reaction monitoring in patients of oral cavity malignancies attending radiotherapy department in a tertiary care teaching institute. Indian J Pharm Pharmacol 2017;4(1):38-41

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.